Stereotactic body RT promising for low-, intermediate-risk PCa

Stereotactic body RT promising for low-, intermediate-risk PCa

(HealthDay)—In men with low-risk and intermediate-risk prostate cancer, stereotactic body radiotherapy is associated with low rates of severe toxic events and high rates of biochemical control, according to a study published online Feb. 8 in JAMA Network Open.

Amar U. Kishan, M.D., from the University of California in Los Angeles, and colleagues assessed long-term outcomes after stereotactic body for and intermediate-risk prostate cancer. A total of 2,142 men (mean age, 67.9 years) who participated in phase 2 between 2000 and 2012 were followed from Jan. 1, 2013, to May 1, 2018 (median follow-up, 6.9 years).

The researchers found that the seven-year cumulative rates of biochemical recurrence were 4.5 percent for low-risk disease, 8.6 percent for favorable intermediate-risk disease, 14.9 percent for unfavorable intermediate-risk disease, and 10.2 percent for all intermediate-risk . The crude incidence of acute grade 3 or higher genitourinary toxic events and gastrointestinal toxic events was 0.6 and 0.09 percent, respectively. For late grade 3 or higher genitourinary toxic events, the seven-year cumulative incidence was 2.4 percent; it was 0.4 percent for gastrointestinal toxic events.

"These data suggest that stereotactic body radiotherapy is an appropriate definitive treatment modality for low-risk and intermediate-risk prostate cancer," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.


Explore further

Shorter course of radiation therapy effective in treating men with prostate cancer

More information: Abstract/Full Text
Journal information: JAMA Network Open

Copyright © 2019 HealthDay. All rights reserved.

Citation: Stereotactic body RT promising for low-, intermediate-risk PCa (2019, March 5) retrieved 4 July 2020 from https://medicalxpress.com/news/2019-03-stereotactic-body-rt-low-intermediate-risk.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments